WHO Suspends Procurement, Supply of Bharat Biotech Covid Vaccine
(Bloomberg) -- The World Health Organization suspended procurement and supply of Covaxin, a Covid-19 vaccine made by Bharat Biotech International Ltd., citing issues following an inspection at the company's facilities.
The Indian vaccine maker has committed to address deficiencies in good manufacturing practices and is developing a corrective and preventive action plan, the World Health Organization said, without specifying when the suspension will be lifted. It recommended countries which have received the vaccine to “take actions as appropriate.”
The World Health Organization granted emergency use authorization to the vaccine co-developed by India's medical research agency and the local manufacturer in November. It said the suspension doesn't change the vaccine's risk assessment, and data indicates it is effective and no safety concerns exist.
Bharat Biotech on Friday said it will temporarily slow down production of Covaxin across its manufacturing facilities as it had completed supply obligations and expected a decrease in demand.
“Bharat Biotech agreed with the WHO team on the scope of the planned improvement activities and indicated that they will be executed as soon as practical,” it also said.
A spokesperson for Bharat Biotech declined to comment further on Sunday. India's federal health ministry spokeswoman didn't immediately respond to requests seeking comment outside of regular business hours. More than 308 million doses of Covaxin have been administered across India, according to government data.
Read more: WHO Approves Indian-Made Covid-19 Vaccine for Emergency Use
©2022 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
